Pulmonary Fibrosis Related to Amiodarone-Is It a Standard Pathophysiological Pattern? A Case-Based Literature Review

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2022 Dec 23

PMID 36553223

Authors

Corina Eugenia Budin

Iuliu Gabriel Cocuz

Adrian Horatiu Sabau

Raluca Niculescu

Ingrid Renata Ianosi

Vladimir Ioan

Ovidiu Simion Cotoi

Affiliations

Soon will be listed here.

Abstract

Amiodarone hydrochloride is an antiarrhythmic drug, with proven efficacy in prevention and treatment of numerous arrhythmias, atrial fibrillation especially, or ventricular arrhythmias, with a long half-life (55-60 days). The increased risk of developing amiodarone-induced pulmonary fibrosis is directly related to the dose and the duration of the intake. Amiodarone-induced pulmonary toxicity is conditioned by dose, patient's age, and pre-existent pulmonary pathologies. The pattern for drug-induced lung injury may vary in many forms, but the amiodarone can cause polymorphous injuries such as diffuse alveolar damage, chronical interstitial pneumonia, organizing pneumonia, pulmonary hemorrhage, lung nodules or pleural disease. The pathological mechanism of pulmonary injury induced by amiodarone consists of the accumulation of phospholipid complexes in histocytes and type II pneumocytes. Differential diagnosis of pulmonary fibrosis induced by amiodarone is made mainly with idiopathic pulmonary fibrosis, left ventricular failure or infectious disease. Before starting treatment with amiodarone, patients should be informed of potential adverse effects and any new respiratory symptoms should promptly be reported to their family physician or attending physician. The assessment carried out at the initiation of amiodarone treatment should include at least chest X-ray and respiratory function tests and extrapulmonary evaluation.

Citing Articles

Evaluation of a non-animal toolbox informed by adverse outcome pathways for human inhalation safety.

de Avila R, Muller I, Barlow H, Middleton A, Theiventhran M, Basili D Front Toxicol. 2025; 7:1426132.

PMID: 40061084 PMC: 11885506. DOI: 10.3389/ftox.2025.1426132.

Amiodarone-induced ocular and extra-ocular toxicity: a retrospective cohort study.

Dammacco R, Guerriero S, Cardia G, Alessio G, Vacca A, Dammacco F Clin Exp Med. 2025; 25(1):68.

PMID: 40025381 PMC: 11872752. DOI: 10.1007/s10238-025-01569-3.

An exploration into CTEPH medications: Combining natural language processing, embedding learning, in vitro models, and real-world evidence for drug repurposing.

Steiert D, Wittig C, Banerjee P, Preissner R, Szulcek R PLoS Comput Biol. 2024; 20(9):e1012417.

PMID: 39264975 PMC: 11478854. DOI: 10.1371/journal.pcbi.1012417.

Analysis of a Serious Adverse Reaction of Pulmonary Fibrosis Caused by Dronedarone.

Chen Y, Fu Z, Wen X, Zhang M, Min Q, Wang P Curr Ther Res Clin Exp. 2024; 100:100743.

PMID: 38617895 PMC: 11015333. DOI: 10.1016/j.curtheres.2024.100743.

Autopsy of Drug-induced Lung Injury with Atypical Diffuse Alveolar Disorder due to Amiodarone.

Mamizu H, Kohda H, Tomita Y, Hatakeyama T, Mamizu M, Ishikawa D Intern Med. 2024; 63(19):2661-2666.

PMID: 38403765 PMC: 11518590. DOI: 10.2169/internalmedicine.3141-23.

References

Andrade J, Connolly S, Dorian P, Green M, Humphries K, Klein G . Antiarrhythmic use from 1991 to 2007: insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II). Heart Rhythm. 2010; 7(9):1171-7. DOI: 10.1016/j.hrthm.2010.04.026. View

Udagawa C, Horinouchi H, Shiraishi K, Kohno T, Okusaka T, Ueno H . Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease. PLoS One. 2019; 14(10):e0223371. PMC: 6777826. DOI: 10.1371/journal.pone.0223371. View

Mankikian J, Favelle O, Guillon A, Guilleminault L, Cormier B, Jonville-Bera A . Initial characteristics and outcome of hospitalized patients with amiodarone pulmonary toxicity. Respir Med. 2014; 108(4):638-46. DOI: 10.1016/j.rmed.2014.01.014. View

Dharmarajan T, Shah A, Dharmarajan L . Amiodarone-induced pulmonary toxicity: potentially fatal, recognize early during life!. J Am Geriatr Soc. 2008; 56(7):1363-5. DOI: 10.1111/j.1532-5415.2008.01715.x. View

Schwaiblmair M, Berghaus T, Haeckel T, Wagner T, von Scheidt W . Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect?. Clin Res Cardiol. 2010; 99(11):693-700. DOI: 10.1007/s00392-010-0181-3. View

Malaviya R, Kipen H, Businaro R, Laskin J, Laskin D . Pulmonary toxicants and fibrosis: innate and adaptive immune mechanisms. Toxicol Appl Pharmacol. 2020; 409:115272. PMC: 9960630. DOI: 10.1016/j.taap.2020.115272. View

Terzo F, Ricci A, DAscanio M, Raffa S, Mariotta S . Amiodarone-induced pulmonary toxicity with an excellent response to treatment: A case report. Respir Med Case Rep. 2019; 29:100974. PMC: 6911974. DOI: 10.1016/j.rmcr.2019.100974. View

Chen Y, Avery A, Neil K, Johnson C, Dewey M, Stockley I . Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf. 2005; 28(1):67-80. DOI: 10.2165/00002018-200528010-00005. View

Roelandt M, Demedts M, Callebaut W, Coolen D, Slabbynck H, Bockaert J . Epidemiology of interstitial lung disease (ILD) in flanders: registration by pneumologists in 1992-1994. Working group on ILD, VRGT. Vereniging voor Respiratoire Gezondheidszorg en Tuberculosebestrijding. Acta Clin Belg. 1995; 50(5):260-8. DOI: 10.1080/17843286.1995.11718459. View

10.

Olshansky B, Sami M, Rubin A, Kostis J, Shorofsky S, Slee A . Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study. Am J Cardiol. 2005; 95(3):404-5. DOI: 10.1016/j.amjcard.2004.09.044. View

11.

Travis W, Costabel U, Hansell D, King Jr T, Lynch D, Nicholson A . An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013; 188(6):733-48. PMC: 5803655. DOI: 10.1164/rccm.201308-1483ST. View

12.

Al-Khatib S, Stevenson W, Ackerman M, Bryant W, Callans D, Curtis A . 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical.... Heart Rhythm. 2017; 15(10):e190-e252. DOI: 10.1016/j.hrthm.2017.10.035. View

13.

Kang I, Kim K, Kim Y, Park S . The diagnostic utility of chest computed tomography scoring for the assessment of amiodarone-induced pulmonary toxicity. Korean J Intern Med. 2014; 29(6):746-53. PMC: 4219964. DOI: 10.3904/kjim.2014.29.6.746. View

14.

Skeoch S, Weatherley N, Swift A, Oldroyd A, Johns C, Hayton C . Drug-Induced Interstitial Lung Disease: A Systematic Review. J Clin Med. 2018; 7(10). PMC: 6209877. DOI: 10.3390/jcm7100356. View

15.

Larsen B, Vaszar L, Colby T, Tazelaar H . Lymphoid hyperplasia and eosinophilic pneumonia as histologic manifestations of amiodarone-induced lung toxicity. Am J Surg Pathol. 2012; 36(4):509-16. DOI: 10.1097/PAS.0b013e318243fd9a. View

16.

Epstein A, Olshansky B, Naccarelli G, Kennedy Jr J, Murphy E, Goldschlager N . Practical Management Guide for Clinicians Who Treat Patients with Amiodarone. Am J Med. 2015; 129(5):468-75. DOI: 10.1016/j.amjmed.2015.08.039. View

17.

Cabrera-Rego J, Luzurriaga Navas J, Yanes Quintana A . [Acute amiodarone pulmonary toxicity with low impregnation dose: case report]. Medwave. 2020; 20(7):e7996. DOI: 10.5867/medwave.2020.07.7996. View

18.

Zhang H, Sulzer D . Frequency-dependent modulation of dopamine release by nicotine. Nat Neurosci. 2004; 7(6):581-2. DOI: 10.1038/nn1243. View

19.

Meziani L, Mondini M, Petit B, Boissonnas A, de Montpreville V, Mercier O . CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages. Eur Respir J. 2018; 51(3). DOI: 10.1183/13993003.02120-2017. View

20.

Wolkove N, Baltzan M . Amiodarone pulmonary toxicity. Can Respir J. 2009; 16(2):43-8. PMC: 2687560. DOI: 10.1155/2009/282540. View